SEARCH

SEARCH BY CITATION

References

  • Arce P. M., Khdour O. M., Goldschmidt R., Armstrong J. S. and Hecht S. M. (2011) A strategy for suppressing redox stress within mitochondria. ACS Med. Chem. Lett. 2, 608613.
  • Arnold P., Boulat O., Mairec R and Kuntzer T. (2006) Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweizer Archiv. Neurol. Psychiatr. 157, 169176.
  • Artuch R., Aracil A., Mas A., Colomé C., Rissech M., Monrós E. and Pineda M. (2002) Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33, 190193.
  • Artuch R., Aracil A., Mas A., Monrós E., Vilaseca M. A. and Pineda M. (2004) Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics 35, 9598.
  • Bentinger M., Dallner G., Chojnacki T. and Swiezewska E. (2003) Distribution and breakdown of lebeled coenzyme Q10 in rat. Free Radic. Biol. Med. 34, 563575.
  • Bentinger M., Tekle M. and Dallner G. (2010) Coenzyme Q – Biosynthesis and functions. Biochem. Biophys. Res. Commun. 396, 7479.
  • Bhagavan H. N. and Chopra R. K. (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 40, 445453.
  • Bhagavan H. N. and Chopra R. K. (2007) Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 7(Suppl), S78S88.
  • Bradley J. L., Blake J. C., Chamberlain S., Thomas P. K., Cooper J. M. and Schapira A. H. V. (2000) Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 9, 275282.
  • Brandsema J. F., Stephens D., Hartley J. and Yoon G. (2010) Intermediate-dose idebenone and quality of life in Friedreich ataxia. Pediatr. Neurol. 42, 338342.
  • Buyse G., Mertens L., Di Salvo G., Matthijs I., Weidemann F., Eyskens B., Goossens W., Goemans N., Sutherland G. R. and Van Hove J. L. K. (2002) Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60, 16791681.
  • Campuzano V., Montermini L., Dolores Moltò M. et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 14231427.
  • Campuzano V., Montermini L., Lutz Y. et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 17711780.
  • Cooper J. M., Korlipara L. V. P., Hart P. E., Bradley J. L. and Schapira A. H. V. (2008) Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15, 13711379.
  • Delatycki M. B., Camakaris J., Brooks H., Evans-Whipp T., Thorburn D. R., Williamson R. and Forrest S. M. (1999) Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673675.
  • Di Prospero N. A., Baker A., Jeffries N. and Fischbeck K. H. (2007a) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878886.
  • Di Prospero N. A., Sumner C. J., Penzak S. R., Ravina B., Fischbeck K. H. and Taylor J. P. (2007b) Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch. Neurol. 64, 803808.
  • Drinkard B. E., Keyser R. E., Paul S. M., Arena R., Plehn J. F., Yanovski J. A. and Di Prospero N. A. (2010) Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch. Phys. Med. Rehabil. 91, 10441050.
  • Duberley K. E. C., Hargreaves I. P., Chaiwatanasirikul K.-A., Heales S. J. R., Land J. M., Rahman S., Mills K. and Eaton S. (2013) Coenzyme Q10 quantification in muscle, fibroblasts and cerebrospinal fluid by liquid chromatography/tandem mass spectrometry using a novel deuterated internal standard. Rapid Commun. Mass Spectrom. 27, 924930.
  • Dürr A., Cossée M., Agid Y., Campuzano V., Miganrd C., Penet C., Mandel J.-L., Brice A. and Koenig M. (1996) Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 11691175.
  • Emond M., Lepage G., Vanasse M. and Pandolfo M. (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55, 17531753.
  • Esposti M. D., Ngo A., Ghelli A., Benelli B., Carelli V., McLennan H. and Linnane A. W. (1996) The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch. Biochem. Biophys. 330, 395400.
  • Evans D. R. and Guy H. I. (2004) Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 279, 3303533038.
  • Fash D. M., Khdour O. M., Sahdeo S. J., Goldschmidt R., Jaruvangsanti J., Dey S., Arce P. M., Collin V. C., Cortopassi G. A. and Hecht S. M. (2013) Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection. Bioorg. Med. Chem. 21, 23462354.
  • Gane E. J., Weilert F., Orr D. W., Keogh G. F., Gibson M., Lockhart M. M., Frampton C. M., Taylor K. M., Smith R. A. and Murphy M. P. (2010) The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 30, 10191026.
  • Giacchetti M., Monticelli A., De Biase I., Pianese L., Turano M., Filla A., De Michele G. and Cocozza S. (2004) Mitochondrial DNA haplogroups influence the Friedreich's ataxia phenotype. J. Med. Genet. 41, 293295.
  • Giunti P., Greenfield J., Stevenson A. J., Parkinson M. H., Hartmann J. H., Sandtmann R., Piercy J., O'Hara J., Ruiz-Casas L. and Smith F. M. (2013) Impact of Friedreich's ataxia on healthcare resource utilization in the United Kingdom and Germany. Orphanet J. Rare Dis. 8, 38.
  • Harding A. (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589620.
  • Hargreaves I. P. (2003) Ubiquinone: cholesterol's reclusive cousin. Ann. Clin. Biochem. 40, 207218.
  • Hart P. E., Lodi R., Rajagopalan B. et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621626.
  • Hausse A. O., Aggoun Y., Bonnet D., Sidi D., Munnich A., Rötig A. and Rustin P. (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87, 346349.
  • Heidari M. M., Houshmand M., Hosseinkhani S., Nafissi S., Scheiber-Mojdehkar B. and Khatam M. (2009) A novel mitochondrial heteroplasmic C13806A point mutation associated with Iranian Friedreich's ataxia. Cell. Mol. Neurobiol. 29, 225233.
  • Houshmand M., Panahi M. S. S., Nafisi S., Soltanzadeh A. and Alkandari F. M. (2006) Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia. Mitochondrion 6, 8793.
  • Kaikkonen J., Tuomaine T.-P., Nyyssönen K. and Salonen J. T. (2002) Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic. Res. 36, 389397.
  • Kwong L. K., Kamzalov S., Rebrin I., Bayne A.-C. V., Jana C. K., Morris P., Forster M. J. and Sohal R. (2002) Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic. Biol. Med. 33, 627638.
  • Lagedrost S. J., Sutton M. S., Cohen M. S., Satou G. M., Kaufman B. D., Perlman S. L., Rummey C., Meier T. and Lynch D. R. (2011) Idebenone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA). Am. Heart J. 161, 639645.
  • Lamperti C., Naini A., Hirano M. et al. (2003) Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 60, 12061208.
  • Lenaz G., Fato R., Formiggini G. and Genova M. L. (2007) The role of coenzyme Q in mitochondrial electron transport. Mitochondrion 7(Suppl), S8S33.
  • Lodi R., Cooper J. M., Bradley J. L., Manners D., Styles P., Taylor D. J. and Schapira A. H. V. (1999) Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 1149211495.
  • Lodi R., Hart P. E., Rajagopalan B. et al. (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 49, 590596.
  • Lynch D. R., Perlman S. L. and Meier T. (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67, 941947.
  • Mariotti C., Solari A., Torta D., Marano L., Fiorentini C. and Di Donato S. (2002) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60, 16761679.
  • Matthews R. T., Yang L., Browne S., Baik M. and Beal M. F. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl Acad. Sci. USA 95, 88928897.
  • Meier T. and Buyse G. (2009) Idebenone: an emerging therapy for Friedreich ataxia. J. Neurol. 256(Suppl 1), 2530.
  • Meier T., Perlman S. L., Rummey C., Coppard N. J. and Lynch D. R. (2012) Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 259, 284291.
  • Metz G., Coppard N., Cooper J. M. et al. (2013) Rating disease progression of Friedreich's ataxia by the international cooperative ataxia rating scale: analysis of a 603-patient database. Brain 136, 259268.
  • Nagai Y., Yoshida K., Narumi S., Tanayama S. and Nagaoka A. (1989) Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats. Arch. Gerontol. Geriatr. 8, 257272.
  • Orsucci D., Mancuso M., Caldarazzo Ienco E., LoGerfo A. and Siciliano G. (2011) Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr. Med. Chem. 18, 40534064.
  • Pandolfo M. and Pastore A. (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 256(Suppl 1), 917.
  • Piemonte F., Pastore A., Tozzi G., Tagliacozzi D., Santorelli F. M., Carrozzo R., Casali C., Damiano M., Federici G. and Bertini E. (2001) Glutathione in blood of patients with Friedreich's ataxia. Eur. J. Clin. Invest. 31, 10071011.
  • Pineda M., Arpa J., Montero R. et al. (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470475.
  • Ribaï P., Pousset F., Tanguy M.-L. et al. (2007) Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch. Neurol. 64, 558564.
  • Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A. and Rustin P. (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17, 215217.
  • Rustin P., von Kleist-Retzow J.-C., Chantrel-Groussard K., Sidi D., Munnich A. and Rötig A. (1999) Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354, 477479.
  • Rustin P., Rötig A., Munnich A. and Sidi D. (2002) Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. 36, 467469.
  • Rustin P., Bonnet D., Rötig A., Munnich A. and Sidi D. (2004) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial (letter). Neurology 62, 524525.
  • Santhera Pharmaceuticals. (2010) Press Statement, 20 May 2010: Santhera's MICONOS Trial with Catena®/Sovrima® in Friedreich's Ataxia Misses Primary Endpoint. http://www.santhera.com/index.php?docid=212&vid=&lang=&newsdate=201005&newsid=1417424&newslang=en. [accessed on 8 February 2013].
  • Schöls L., Vorgerd M., Schillings M., Skipka G. and Zange J. (2001) Idebenone in patients with Friedreich ataxia. Neurosci. Lett. 306, 169172.
  • Schulz J. B., Dehmer T., Schöls L. et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55, 17191721.
  • Seznec H., Simon D., Monassier L., Criqui-Filipe P., Gansmuller A., Rustin P., Koenig M. and Puccio H. (2004a) Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 13, 10171024.
  • Seznec H., Wilson W. B. and Puccio H. (2004b) 2003 International Friedreich's ataxia research conference,14–16 February 2003, Bethesda, MD, USA. Neuromuscul. Disord. 14, 7082.
  • Shults C. W., Beal M. F., Song D. and Fontaine D. (2004) Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188, 491494.
  • Smith R. A. J. and Murphy M. P. (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci. 1201, 96103.
  • Smith K. M., Matson S., Matson W. R., Cormier K., Del Signore S. J., Hagerty S. W., Stack E. C., Ryu H. and Ferrante R. J. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616626.
  • Snow B. J., Rolfe F. L., Lockhart M. M., Frampton C. M., O'Sullivan J. D., Fung V., Smith R. A., Murphy M. P. and Taylor K. M. (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 16701674.
  • Sugiyama Y., Fujita T., Matsumoto M., Okamoto K. and Imada I. (1985) Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J. Pharmacobio-dyn. 8, 10061017.
  • Suno M. and Nagaoka A. (1984) Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jpn. J. Pharmacol. 35, 196200.
  • Torii H., Yoshida K., Kobayashi T., Tsukamoto T. and Tanayama S. (1985) Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs. J. Pharmacobio-dyn. 8, 457467.
  • Turunen M., Appelkvist E.-L., Sindelar P. and Dallner G. (1999) Blood concentration of coenzyme Q10 increases in rats when esterified forms are administered. J. Nutr. 129, 21132118.
  • Velasco-Sánchez D., Aracil A., Montero R. et al. (2011) Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10, 18.
  • Weidemann F., Rummey C., Bijnens B., Stoörk S., Jasaityte R., Dhooge J., Baltabaeva A., Sutherland G., Schulz J. B. and Meier T. (2012) The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 125, 16261634.
  • Wilson R. B. and Roof D. M. (1997) Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. 16, 352357.